Hormonal
GLP-1 receptor agonists (GLP-1RAs) promote sustained weight loss in adults with obesity or type 2 diabetes primarily by increasing energy expenditure and reducing food intake via central nervous system satiety signaling, independent of glycaemic control.
If you have obesity or Type 2 Diabetes, GLP-1 medications like semaglutide or liraglutide are proven to help you lose significant weight (around 15% in trials) by reducing hunger and increasing energy burn. They are taken as a weekly or daily injection, often alongside diet and exercise changes. These are not quick fixes but chronic treatments that mimic a natural gut hormone to help regulate your body's weight set-point.
pharmacokinetic investigation in human participants suggested the effects of liraglutide on weight loss are primarily mediated through increased energy expenditure (66). ... GLP-1 crosses the blood-brain barrier to agonise GLP-1R within hypothalamic CNS centres, where ingestive behaviour and satiety is dictated [(117); Figure 3]. Increased satiety reduces food intake, with resultant weight loss being an important benefit in overweight or obese-T2DM patients.
Why this rating
The paper cites multiple large-scale Phase III clinical trials (SCALE, SUSTAIN) and long-term prospective outcomes, indicating high-quality clinical evidence.
Source
Proglucagon-Derived Peptides as Therapeutics
Ryan A. Lafferty et al. · Frontiers in Endocrinology · 2021
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →